Literature DB >> 24024541

Under-recognition and under-treatment of DSM-IV classified mood and anxiety disorders among disability claimants.

Bert Cornelius1, Jac J L van der Klink, Sandra Brouwer, Johan W Groothoff.   

Abstract

PURPOSE: This study aimed to examine under-recognition, under-treatment and severity of under-treated DSM-IV mood and anxiety disorders among disability claimants.
METHODS: In a representative sample of Dutch disability claimants (n = 346), registry codes certified according to the International Classification of Diseases 10th edition (ICD-10) by insurance physicians, were compared with classifications according to the Diagnostic Statistical Manual of Mental Disorders (DSM-IV) detected by the Composite International Diagnostic Interview (CIDI). Levels of ICD-10/DSM-IV agreement were assessed for mood and anxiety disorders in the total sample, and prevalence of recent DSM-IV mood and anxiety disorders in a pure ICD-10 somatic subgroup. Treatment and severity of under-treated DSM-IV mood and anxiety disorders were assessed in two subgroups of disability claimants with either an ICD-10 somatic or mental disorder as primary cause of disability, irrespective of any ICD-10 comorbidity.
RESULTS: Levels of ICD-10/DSM-IV agreement were poor (κ: 0.237 for mood and 0.260 for anxiety disorders). In the pure ICD-10 somatic subgroup, the prevalence of DSM-IV mood and anxiety disorders was 3.8% and 11.4%, respectively. In the ICD-10 somatic subgroup irrespective of any ICD-10 comorbidity, 45.2% (major depressive disorder), 80.0% (social phobia) and 53.3% (general anxiety disorder) were under-treated. In the ICD-10 mental subgroup, these percentages were 44.7%, 80.9% and 33.4%, respectively. In both of these subgroups, under-treated DSM-IV mood and anxiety disorders were predominantly serious in terms of impairment and disability.
CONCLUSIONS: Serious mental disorders were found to be substantially under-diagnosed and under-treated among disability claimants. To optimize diagnosis and treatment of disabling mental disorder, medical professionals in insurance, occupational and in the health care sector should closely collaborate. For claimants with under-treated mental disorders, tailor-made multidisciplinary interventions are needed to promote return to work and to prevent permanent disability.

Entities:  

Keywords:  Anxiety disorder; diagnosis; disability claimants; mood disorder; treatment

Mesh:

Year:  2013        PMID: 24024541     DOI: 10.3109/09638288.2013.833310

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  5 in total

1.  Development and validation of the Diagnostic Interview Adjustment Disorder (DIAD).

Authors:  L R Cornelius; S Brouwer; M R de Boer; J W Groothoff; J J L van der Klink
Journal:  Int J Methods Psychiatr Res       Date:  2014-01-30       Impact factor: 4.035

2.  Predictors of functional improvement and future work status after the disability benefit claim: a prospective cohort study.

Authors:  L R Cornelius; J J L van der Klink; M R de Boer; J W Groothoff; S Brouwer
Journal:  J Occup Rehabil       Date:  2014-12

Review 3.  Determinants of Sickness Absence and Return to Work Among Employees with Common Mental Disorders: A Scoping Review.

Authors:  Haitze de Vries; Alba Fishta; Beate Weikert; Alejandra Rodriguez Sanchez; Uta Wegewitz
Journal:  J Occup Rehabil       Date:  2018-09

4.  Self-reported insomnia as a marker for anxiety and depression among migraineurs: a population-based cross-sectional study.

Authors:  Kyung Min Kim; Dong Hyun Lee; Eun Ju Lee; Yun Ho Roh; Won-Joo Kim; Soo-Jin Cho; Kwang Ik Yang; Chang-Ho Yun; Min Kyung Chu
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

5.  Depressive symptoms, but not anxiety, predict subsequent diagnosis of Coronavirus disease 19: a national cohort study.

Authors:  G Meinlschmidt; S Guemghar; N Roemmel; E Battegay; S Hunziker; R Schaefert
Journal:  Epidemiol Psychiatr Sci       Date:  2022-03-25       Impact factor: 6.892

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.